<DOC>
	<DOCNO>NCT00218660</DOCNO>
	<brief_summary>The purpose study see whether naltrexone safe useful prevent alcohol relapse , well decrease crave alcohol people diagnosis alcohol cocaine dependence . Naltrexone approve Food Drug Administration ( FDA ) treatment alcohol dependence . However , medication approve yet dosage use study . The dosage use study ( 150 mg ) , great recommend dosage Physician 's Desk Reference ( 50mg ) . Unlike medicine ( like Antabuse ) useful treatment alcohol dependence , naltrexone make sick drink alcohol . Rather , people take medication report helps decrease pleasure associate drinking . This study conduct medication ( Naltrexone ) well studied people alcohol cocaine dependence , still investigational . We believe reduce alcohol consumption naltrexone psychotherapy , may lead reduce cocaine use . We also conduct study test two different type psychotherapy method reduce cocaine alcohol use . One type psychotherapy , CBT , design help people learn cope situation put high risk relapse cocaine and/or alcohol use . The type psychotherapy , BRENDA , use focus strengthen motivation recover cocaine and/or alcohol use , develop technique handle possible barrier recovery . We seek enroll 300 patient study .</brief_summary>
	<brief_title>Naltrexone Two Models Psychosocial Treatments Cocaine Alcohol Dependence - 1</brief_title>
	<detailed_description>The project use 2x2 design ass efficacy naltrexone treat subject cocaine alcohol dependent receive either CBT BRENDA alone combination naltrexone . There 300 DSM-IV cocaine-alcohol dependent male female subject randomize one four group ( 75 subject per group ) . Subjects randomize either 150mg/day naltrexone placebo receive either CBT ( type cognitive behavior therapy derive relapse prevention principle ) , new primary-care basedmodel , BRENDA , comprise strategy enhance motivation treatment compliance . All subject receive one four combination medication psychosocial treatment . The length study subject include one week screening/baseline assessment , 12 week double-blind , placebo-controlled naltrexone treatment combine one two psychosocial treatment , 6-month 12-month follow-up visit . Following successful completion detoxification ( abstinence alcohol cocaine 7 day ) , informed consent sign , Week 1 devote complete screen baseline measure . In Week 2 , subject randomly assign medication/ psychosocial treatment combination . Following completion 12-week , double-blind treatment trial , subject evaluate 6-month 12-months post-treatment visit .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Cocaine-Related Disorders</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Cocaine</mesh_term>
	<criteria>Male female , 1865 year old . Meets DSMIV criterion current diagnosis cocaine alcohol dependence , determine SCID . In past 30 day , S use less $ 200worth cocaine &gt; 15 standard alcohol drink ( avg ) /week least 1 day 4 drink , determine TLFBadapted collect daily cocaine use . Successful completion alcohol detoxification , i.e. , 5 consecutive day abstinence cocaine alcohol , via selfreports negative urine toxicology screen . Lives commutable distance TRC agree followup visit . Understands sign consent . Abstinent cocaine alcohol 30 day prior sign consent form . ( S may institutionalize prior month still eligible his/her cocaine alcohol use month meet inclusion criterion . ) Current DSMIV diagnosis substance dependence cocaine , alcohol , nicotine , cannabis determine SCID . Evidence opiate use past 30 day , determine selfreport SCID ASI , and/or urine drug screen positive opiate treatment entry . Current treatment psychotropic medication ( exclude shortterm use benzodiazepine detoxification ) , include disulfiram . History unstable serious medical illness , include need opioid analgesic . History epilepsy seizure disorder . Known severe physical medical illness AIDS , active hepatitis , significant hepatocellular injury evidence elevated bilirubin level , elevate level 4.5x normal aspartate aminotransferase ( AST ) , serum glutamicpyruvic transaminase ( SGPT ) . Current severe psychiatric symptom , e.g. , psychosis , dementia , acute suicidal homicidal ideation , mania depression require antidepressant therapy , would make unsafe patient participate opinion primary investigator . Use investigational medication past 30 day . Female Ss pregnant , nursing , use reliable method contraception . [ Note : Criteria 410 assess via medical exam plus result lab test . ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>